The study on effectiveness of sublingual immunotherapy with mite extract in patients with atopic dermatitis

The study on effectiveness of sublingual immunotherapy with mite extract in patients with atopic dermatitis - Effectiveness of sublingual immunotherapy with mite extract in patients with atopic dermatitis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029044

Enrollment

Registered

2019-04-01

Start date

2018-03-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

sublingual tablet for house dust mite 3,300 JAU was selected as the initial dose for a week, followed by upward titration of the dose to 10,000 JAU, and continue for 2 ye

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Symptom of rhinitis on medical history (2) Upper than 5 in EASI score (3) Patients with positive skin test and specific IgE antibody for house dust mite (4) Patients who agree with this examination (5) Older than 20 years

Exclusion criteria

Exclusion criteria: (1) Pregnant and breast-feeding patients (2) Patients with severe asthma (3) Patients who take oral corticosteroid and cyclosporine (4) Inappropriate patients in this examination

Design outcomes

Primary

Measure	Time frame
Eczema Area and Severity Index score (1,3,6,12,18,24 months after initiation of sublingual immunotherapy)	—

Secondary

Measure	Time frame
skin test, specific IgE, serum TARC, itchy severity index (VAS), Nasal symptom score	—

Countries

Japan

Contacts

Public ContactMayuko Mizuno

Kobe University Graduate School of Medicine Division of Dermatology, Department of Internal Related

196m858m@stu.kobe-u.ac.jp078-382-6134

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026